nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.06.2008 | Original Paper

The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine

verfasst von: Xiao-Yong Pu, Zhi-Ping Wang, Yi-Rong Chen, Xing-Huan Wang, Yi-Long Wu, Huai-Peng Wang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the value of combined use of survivin, cytokeratin (CK) 20 and mucin (MUC) 7 mRNA in comparison with voided urine cytology in the detection of bladder cancer patients.

Methods

One hundred and fifty three patients and 20 healthy volunteers were evaluated by RT-PCR for detecting survivin, CK-20 and MUC7 mRNA in voided urine before cystoscopy. The three markers and cytology were evaluated independently or in combinations.

Results

The overall sensitivity and specificity were 90.4 and 94.7% for survivin, 82.6 and 97.4% for CK-20, 62.6 and 94.7% for MUC7 and 46.0 and 100% for voided urine cytology. Combined sensitivity of voided urine cytology with the three biomarkers together was higher than either combined sensitivity of voided urine cytology with one of the biomarkers or than that of the biomarker alone.

Conclusions

Combined use of the three markers can improve the sensitivity for detecting bladder cancer.

Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–53PubMedCrossRef

Bobek IA, Tsai H, Biesbrock AR et al (1993) Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7). J Biol Chem 268:20563–20569PubMed

Boman H, Hedelin H, Jacobsson S et al (2002) Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol 168:1955–1959PubMedCrossRef

Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkorn I (1998) Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J Urol 160(6 Pt 1):1971–1974PubMed

Christoph F, Muller M, Schostak M, Soong R, Tabiti K, Miller K (2004) Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 64(1):157–161PubMedCrossRef

Eissa S, Kenawy G, Swellam M, El-Fadle AA, Abd El-Aal AA, El-Ahmady O (2004) Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma. Clin Biochem 37:803–810PubMedCrossRef

Getzenberg RH, Konety BR, Oeler TA et al (1996) Bladder cancer-associated nuclear matrix proteins. Cancer Res 56:1690–1694PubMed

Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRef

Jiang J, Ulbright TM, Younger C et al (2001) Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch Pathol Lab Med 125:921–923PubMed

Kim YS, Gum J Jr, Brockhausen I (1996) Mucin glycoproteins in neoplasia. Glycoconj J 13:693–707PubMedCrossRef

Kim MA, Lee HS, Yang HK, Kim WH (2004) Cytokeratin expression profile in gastric carcinomas. Hum Pathol 35(5):576–581PubMedCrossRef

Klein A, Zemer R, Buchumensky V, Klaper R, Nissenkorn I (1998) Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer 82(2):349–354PubMedCrossRef

Konety BR (2006) Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 24:326–337PubMed

McKenney JK, Desai S, Cohen C, Amin MB (2001) Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p 53, and CD44 antigens. Am J Surg Pathol 25(8):1074–1078PubMedCrossRef

Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger Mand Pycha A (2000) Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 56:228PubMedCrossRef

Miettinen M (1995) Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and merkel cell carcinomas. Mod Pathol 8(4):384–388PubMed

Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK (2006) Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 175:2312–2316PubMedCrossRef

Murphy WM (1990) Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 21:886–896PubMedCrossRef

Okegawa T, Kinjo M, Horie S, Nutahara K, Higashihara E (2003) Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. Urology 62:182–186PubMedCrossRef

Retz M, Lehmann J, Roder C, Plotz B et al (1998) Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma. Cancer Res 58:5662–5666PubMed

Retz M, Lehmann J, Amann E, Wullich B, Roder C. Stockle M (2003) Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J Urol 169(1):86–89PubMedCrossRef

Retz M, Lehmann J, Szysnik C et al (2004) Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. Eur Urol 45:314–319PubMedCrossRef

Rotem D, Cassel A, Lindenfeld N et al (2000) Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur Urol 37(5):601–604PubMedCrossRef

Shamp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM (2002) Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci 7:E36–E41CrossRef

Shariat SF, Casella R, Khoddami SM et al (2004) Urine detection of survivin in a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171(2Pt1):626–630PubMedCrossRef

Shrom SH, Parsons CL, Mulholland SG (1978) Vesical defense: further evidence for a charge-related mucosal anti-adherence mechanism. Surg Forum 29:632–633PubMed

Siracusano S, Niccolini B, Knez R et al (2005) The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine. Eur Urol 47:327–333PubMedCrossRef

Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC (2001) Urine detection of survivin and diagnosis of bladder cancer. JAMA 285:324–328PubMedCrossRef

Sobin LH, Wittkind C (1997) UICC TNM classification of malignant tumors, 5th edn. Wiley Liss, New York, pp 187–190

Swana HS, Grossman D, Anthony JN et al (1999) Tumor content of the antiapoptotic molecule survivin and recurrence of bladder cancer. N Engl J Med 341:452–453PubMedCrossRef

Zippe G, Pandrangi L, Agarwal A (1999) NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 161:62–65PubMedCrossRef

Titel: The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine
verfasst von: Xiao-Yong Pu
Zhi-Ping Wang
Yi-Rong Chen
Xing-Huan Wang
Yi-Long Wu
Huai-Peng Wang
Publikationsdatum: 01.06.2008
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2008
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-007-0331-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine

Abstract

Objectives

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

LAMA4, highly expressed in human hepatocellular carcinoma from Chinese patients, is a novel marker of tumor invasion and metastasis

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound

Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound

Synergistic antitumor effect of CXCL10 with hyperthermia

Subareolar blue dye only injection sentinel lymph node biopsy could reduce the numbers of standard axillary lymph node dissection in environments without access to nuclear medicine

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie